Dilated cardiomyopathy (DCM) is a condition associated with Left and /or right ventricular (LV) dilatation and systolic dysfunction without coronary artery disease or abnormal loading circumstances proportionate to the severity of LV impairment. It is one of the leading causes of heart failure in younger adults, often requiring cardiac transplantation, and is caused by various factors, including myocarditis, alcohol, drug, and metabolic disturbances. About 35% of patients have genetic mutations affecting cytoskeletal, sarcomere, and nuclear envelope proteins. The prognosis depends on the severity and heart remodeling, with the worst outcomes in patients with low ejection fractions or severe diastolic dysfunction.
Although it is more common in men, DCM also occur in women, and hence hormonal factors can play a role in the development of DCM in women. Bromocriptine has been suggested as a potential treatment option. Bromocriptine is a dopamine agonist that is primarily used to treat conditions such as hyperprolactinemia, and acromegaly. However, it has also been studied in the context of heart failure, and some studies have suggested that it may be beneficial in women with Peripartal cardiomyopathy (PPCM), a form of DCM that occurs in the last month of pregnancy or up to five months postpartum.
The mechanism by which bromocriptine may improve left ventricular function in DCM is not fully understood, but it is thought to be related to its ability to reduce prolactin levels. Prolactin is a hormone that has been shown to be elevated in some cases of DCM, and it may contribute to the development and progression of the condition. To date, the use of bromocriptine is recommended for the treatment of pregnancy-related cardiomyopathy (PPCM) due to a significant increase in prolactin levels. However, prolactin level may increase during menstrual cycles of reproductive-age women, which candidates the use of bromocriptine in women of all reproductive ages. The aims of this study is to assess the use of bromocriptine in terms of LV function improvement, overall improvement of heart failure symptoms and reduced mortality and improved quality of life, in dilated cardiomyopathy among women of reproductive age.
Jimma, Oromia 378, Ethiopia
Age 18 years to 50 years
ischemic or de novo dilated cardiomyopathy
Patients with severe comorbidities which may worsen their illness
with hypertensive heart diseases
Rheumatic valvular heart diseases
Restrictive cardiomyopathy, constrictive cardiomyopathy, hypertrophic cardiomyopathy
Congenital heart diseases
Acute coronary syndrome
Overt kidney failure (serum Creatinine ≥ 1.4mg/dl),
Women who are pregnant or lactating
Previous adverse reaction to the bromocriptine
Patients not willing to participate in the study
Study Contact Info
Contact Listings Owner Form
Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age 0 reviewsWrite Your Review
There are no reviews yet.